Anti-Angiogenesis Soluble Receptor
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado:: 27 de septiembre de 2005
- VEGF Trap is a fully human fusion protein designed from components of VEGFR-1 and -2. It is soluble (travels freely in blood) and is able to bind VEGF-A more tightly than monoclonal antibodies. In addition to VEGF-A, this drug also blocks placental growth factor (PIGF), another angiogenic substance that is thought to play a role in tumor angiogenesis.
- VEGF Trap has a relatively long half-life of approximately two weeks.
- The MTD has not yet been reached, and the most common adverse events observed were fatigue, pain, and constipation.
- There is an ongoing phase I, open-label, dose-escalation study of intravenous VEGF Trap in patients with advanced cancers are promising.
- Preliminary efficacy analysis shows tumor size reduction and prolonged stable disease in some patients after single-agent VEGF Trap. One patient achieved a partial response with disappearance of ascites, two patients had minor responses, and one patient has maintained stable disease for over 11 months to date.
- Phase I studies now accruing include:
- VEGF Trap plus FOLFOX4 chemotherapy (oxaliplatin/5-fluorouracil /leucovorin) in patients with advanced solid tumors
- Single-agent VEGF Trap in patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma